Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...
Please provide your email address to receive an email when new articles are posted on . Patients with atopic dermatitis or plaque psoriasis exhibited improved IGA scores with topical PF-07038124.
DUBLIN--(BUSINESS WIRE)--The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The clinical trial report ...
Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig ...
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. The Big Pharma evaluated three ...
Atopic dermatitis (AD), the most common form of eczema, impacts patients' life trajectories beyond the physical scars. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results